: Ongoing antitrust scrutiny of pharmacy benefit managers (PBMs) and potential changes to Medicare Advantage rates remain key risks for the 2027 fiscal year.
: After a challenging 2024, the company's 2025 revenue hit a record $402.1 billion , with adjusted EPS rising over 24% to $6.75. should i buy cvs stock
: The acquisition of assets from bankrupt rival Rite Aid has added roughly 9 million new patients to its pharmacy network. Potential Risks to Consider : Ongoing antitrust scrutiny of pharmacy benefit managers